IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease
Zhong, Nanshan1; Zheng, Jinping1; Wen, Fuqiang2; Yang, Lan3; Chen, Ping4; Xiu, Qingyu5; Yao, Wanzhen6; Sun, Tieying7; Zhao, Ziwen8; Shen, Huahao9; Shi, Yi10; Lin, Jiangtao; Li, Qiang12
关键词Budesonide/formoterol chronic obstructive pulmonary disease dry powder inhaler Lung function
刊名CURRENT MEDICAL RESEARCH AND OPINION
2012-02-01
DOI10.1185/03007995.2011.636420
28期:2页:257-265
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]RESPIRATORY QUESTIONNAIRE ; FLUTICASONE ; SALMETEROL ; THERAPY
英文摘要

Objective:

To evaluate the efficacy and safety of budesonide (BUD)/formoterol (FORM) compared with BUD, both administered by way of a dry powder inhaler (Turbuhaler*).

Methods:

This was a 6-month, multicenter, randomized, parallel-group, double-blind, double-dummy design study (NCT 00421122). Patients were randomized to either BUD/FORM 160/4.5 mu g, two inhalations twice daily, or BUD 200 mg, two inhalations twice daily. Improvement of lung function, daily symptoms, reliever use and health-related quality-of-life (St George′s Respiratory Questionnaire [SGRQ] score) were compared between the two treatment groups.

Results:

A total of 308 patients with moderate to very severe COPD from 12 centers in China were randomized to BUD/FORM (n = 156) or BUD (n = 152). The primary endpoint, 1-hour post-dose forced expiratory volume in 1 second (FEV1), in the BUD/FORM group improved by 0.18 L (from 0.83 L at baseline to 1.01 L) and this was significantly better (p<0.001) than the small increase (0.03 L) observed in the BUD group after 24 weeks′ treatment. Increases in pre-dose and 15-min post-dose FEV1 together with 1-hour post-dose forced vital capacity were also significantly larger with BUD/FORM than BUD (p<0.001 for all). Compared with BUD alone, BUD/FORM improved COPD total symptom scores (-1.04 +/- 0.16 vs. -0.55 +/- 0.17; p = 0.03), reduced reliever use (-0.85 +/- 0.16 puffs/day vs. -0.31 +/- 0.16 puffs/day; p = 0.012) and improved health-related quality-of-life (mean change of total SGRQ score -4.5 points (p = 0.0182). Overall, both treatments were well tolerated.

Conclusions:

In Chinese patients with moderate to very severe COPD, fixed combination treatment with BUD/FORM resulted in clinically meaningful improvements in lung function, health-related quality-of-life, COPD symptoms and a reduction in reliever use, compared with BUD alone and both treatments were well tolerated. Treatment of BUD/FORM for milder patients with COPD and head to head comparison of Chinese and Caucasians in future studies will be helpful to expand upon the findings of the current clinical trial.

语种英语
WOS记录号WOS:000299741900011
资助机构AstraZeneca
引用统计
被引频次:10[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63473
专题北京大学第三临床医学院
北京大学第三临床医学院_运动医学研究所
作者单位1.China Japan Friendship Hosp, Beijing, Peoples R China
2.Shanghai Changhai Hosp, Shanghai, Peoples R China
3.Sichuan Univ, W China Hosp, Chengdu 610064, Peoples R China
4.Shenyang Mil Command, Gen Hosp, Shenyang, Peoples R China
5.Shanghai Changzheng Hosp, Shanghai, Peoples R China
6.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
7.Beijing Hosp, Beijing, Peoples R China
8.Guangzhou Med Coll, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou 515120, Guangdong, Peoples R China
9.Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710049, Peoples R China
10.Guang Zhou First Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China
11.Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China
12.Nanjing Mil Command, Nanjing Gen Hosp, Nanjing, Jiangsu, Peoples R China
推荐引用方式
GB/T 7714
Zhong, Nanshan,Zheng, Jinping,Wen, Fuqiang,et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease[J]. CURRENT MEDICAL RESEARCH AND OPINION,2012,28(2):257-265.
APA Zhong, Nanshan.,Zheng, Jinping.,Wen, Fuqiang.,Yang, Lan.,Chen, Ping.,...&Li, Qiang.(2012).Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.CURRENT MEDICAL RESEARCH AND OPINION,28(2),257-265.
MLA Zhong, Nanshan,et al."Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease".CURRENT MEDICAL RESEARCH AND OPINION 28.2(2012):257-265.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhong, Nanshan]的文章
[Zheng, Jinping]的文章
[Wen, Fuqiang]的文章
百度学术
百度学术中相似的文章
[Zhong, Nanshan]的文章
[Zheng, Jinping]的文章
[Wen, Fuqiang]的文章
必应学术
必应学术中相似的文章
[Zhong, Nanshan]的文章
[Zheng, Jinping]的文章
[Wen, Fuqiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。